Cite
HARVARD Citation
de Alarcon, P. et al. (2018). Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet. pp. 25-34. [Online].